View Clinical Trial (Medical Research Study)
An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease - NCT00790933-35233(Clinical Trial 253154)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Birmingham |
|
State:
|
|
AL |
| Zip Code: |
|
35233 |
| Conditions: |
|
Ulcerative Colitis - Crohn's Disease |
| Purpose: |
|
This multicenter, 2-year open-label study will collect data on the occurrence of important
clinical safety events resulting from chronic vedolizumab (MLN0002) administration.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
1. Previous treatment in Study C13004, Study C13006 or Study C13007 that, in the opinion
of the investigator, was well tolerated
2. May be receiving a therapeutic dose of conventional therapies for IBD as defined by
the protocol
Exclusion Criteria:
1. Development of any new, unstable, or uncontrolled disease |
|
|
|
| Study is available at: |
|
University of Alabama at Birmingham
Birmingham, AL 35233
United States
Primary Contact:
Phone: 205-934-7955
Secondary Contact:
For a listing of recruitment sites in your area contact: Millennium Medical and Drug Information Center
Email: medical@mlnm.com
Phone: 1-877-674-3784 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 22, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|